New Drug Approvals

Home » Posts tagged 'doxecitine'

Tag Archives: doxecitine

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,805,707 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

SUBSCRIBE

New Drug Approvals

↑ Grab this Headline Animator

Subscribe in a reader

Enter your email address:

Delivered by FeedBurner

Subscribe to New Drug Approvals by Email

Add to Google Reader or Homepage

Subscribe in Bloglines

Add to The Free Dictionary

I heart FeedBurner

Subscribe in NewsGator Online

Add to netvibes

Add to Excite MIX

Add to fwicki

Add to Webwag

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Doxecitine

January 3, 2026 2:34 am / Leave a comment


Doxecitine

CAS951-77-9

MF C9H13N3O4

11/3/2025, FDA 2025, To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

  • CYTIDINE, 2′-DEOXY-
  • dCYD
  • DEOXYCYTIDINE

4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one

Doxecitine is a pyrimidine nucleoside used to treat thymidine kinase 2 deficiency.

Doxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine. It is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair. Doxecitine is currently approved and marketed as a fixed-dose combination therapy with thymidine (KYGEVVI). This combination is the first and only approved treatment for Thymidine Kinase 2 deficiency.5,6

Deoxycytidine is a deoxyribonucleoside, a component of deoxyribonucleic acid. It is similar to the ribonucleoside cytidine, but with one hydroxyl group removed from the C2′ position. Deoxycytidine can be phosphorylated at C5′ of the deoxyribose by deoxycytidine kinase, converting it to deoxycytidine monophosphate (dCMP), a DNA precursor.[1] dCMP can be converted to dUMP and dTMP.

Doxecitine is the international nonproprietary name.[2]

SYN


Graham A. Mock, Douglas H. Lovern, “N.sup.4 -substituted 2′-deoxycytidine compounds, oligonucleotides including N.sup.4 -labeled 2′-deoxycytidines, and a process for making oligonucleotides with N-modified 2′-deoxycytidines.” U.S. Patent US5633364, issued April, 1995.US5633364

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=US37089691&_cid=P21-MJXONM-10154-1

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO1982003079&_cid=P21-MJXONM-10154-1

str1

AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

wdt-16

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

……

  1. Chow E, Miller L, Clearman A, Arnold P, Koenig MK, Russo SN: Doxecitine and doxribtimine treatment in an adult patient with thymidine kinase 2 deficiency. Mol Genet Metab. 2025 Aug;145(4):109159. doi: 10.1016/j.ymgme.2025.109159. Epub 2025 Jun 3. [Article]
  2. Mittur A, VanMeter SA, Orujov E, Glidden P: Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy Adults. Clin Ther. 2024 Jul;46(7):576-587. doi: 10.1016/j.clinthera.2024.06.006. Epub 2024 Jul 18. [Article]
  3. Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, Juanola-Falgarona M, Barca E, Garcia-Diaz B, Tadesse S, Garone C, Hirano M: Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency. Ann Neurol. 2017 May;81(5):641-652. doi: 10.1002/ana.24922. Epub 2017 May 4. [Article]
  4. FDA Approved Drug Products: KYGEVVI (doxecitine and doxribtimine) powder, for oral solution (November 2025) [Link]
  5. UCB: New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference [Link]
  6. PR Newswire: U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) [Link]
Names
IUPAC name2′-deoxycytidine
Systematic IUPAC name4-Amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one
Other namesdoxecitine
Identifiers
CAS Number951-77-9
3D model (JSmol)Interactive image
ChEBICHEBI:15698
ChEMBLChEMBL66115
ChemSpider13117
ECHA InfoCard100.012.231 
MeSHDeoxycytidine
PubChem CID13711
UNII0W860991D6
CompTox Dashboard (EPA)DTXSID70883620 
InChI
SMILES
Properties
Chemical formulaC9H13N3O4
Molar mass227.217
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).Infobox references

References

  1.  Staub M, Eriksson S (2006). “The Role of Deoxycytidine Kinase in DNA Synthesis and Nucleoside Analog Activation”. In Peters GJ (ed.). Deoxynucleoside Analogs In Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. pp. 29–52. doi:10.1007/978-1-59745-148-2_2. ISBN 978-1-59745-148-2.
  2.  World Health Organization (2022). “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87”. WHO Drug Information. 36 (1). hdl:10665/352794.
  3.  Kim KW, Roh JK, Wee HJ, Kim C (2016). “Molecular Targeted Anticancer Drugs”. In Kim KW, Roh JK, Wee HJ, Kim C (eds.). Cancer Drug Discovery: Science and History. Springer Netherlands. pp. 175–238. doi:10.1007/978-94-024-0844-7_9. ISBN 978-94-024-0844-7.
  4.  Guo M, Zhang L, Du Y, Du W, Liu D, Guo C, et al. (March 2018). “Enrichment and Quantitative Determination of 5-(Hydroxymethyl)-2′-deoxycytidine, 5-(Formyl)-2′-deoxycytidine, and 5-(Carboxyl)-2′-deoxycytidine in Human Urine of Breast Cancer Patients by Magnetic Hyper-Cross-Linked Microporous Polymers Based on Polyionic Liquid”. Analytical Chemistry. 90 (6): 3906–3913. doi:10.1021/acs.analchem.7b04755. PMID 29316399.
  5.  “FDA approves 1st drug for thymidine kinase 2 deficiency”. U.S. Food and Drug Administration. 3 November 2025. Retrieved 4 November 2025. Public Domain This article incorporates text from this source, which is in the public domain.

/////////doxecitine, deoxycytidine, CYTIDINE, 2′-DEOXY-, dCYD, FDA 2025, APPROVALS 2025